Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients

Launched by CENTRE JEAN PERRIN · Aug 22, 2019

Keywords

ClinConnect Summary

The PERCEPTION study is a clinical trial that aims to understand the relationship between certain blood cell counts and tumor-infiltrating lymphocytes (TILs) in women diagnosed with triple negative breast cancer. TILs are immune cells that can be found in tumors and may play a role in how the cancer behaves. The study will look at blood tests and tumor samples before and after surgery to see if these factors can help predict the chance of cancer returning after treatment.

To be eligible for this trial, participants must be women over the age of 18 who have been diagnosed with early-stage, non-metastatic triple negative breast cancer and have received treatments such as chemotherapy, surgery, and radiation. Additionally, participants should be able to understand French and must provide written consent to join the study. Those who participate will help researchers gain valuable insights that could improve future care for patients with this type of breast cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female
• • Age \> 18 years
• • Diagnosed with primitive, non-metastatic, histologically proved, triple negative breast cancer
• • Patient treated with chemotherapy, surgery and radiation therapy
• • Patient able to understand the French language
• • Patient affiliated to social security
• • Obtaining signed written consent
• Exclusion Criteria:
• • Male
• • Unavailable tumoral samples before inclusion
• • Unavailable blood test results at baseline, before inclusion